Floatz logo

Talazoparib

BRCA2-Related Cancer Predisposition

Brown UniversitySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the BRCA2-Related Cancer Predisposition cohort.

Asset / SponsorPhaseRating
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
Olaparib
GBG Forschungs GmbH
Phase 3BB
Ovitrelle
University Hospital, Ghent
Phase 4BB
Niraparib
Qian Qin
Phase 3BB
Letrozole
UNICANCER
Phase 3BB

View all 44 →

Same molecule, other indications

Talazoparib is also rated in:

castration-resistant prostate carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →
Her2-receptor negative breast cancerActive
BB
Indicative · Phase 2
64 / 100
View asset →
renal cell carcinomaDormant
B
Indicative · Phase 2
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →